Skip to main content

RheumNow Week in Review – 4 November 2016

Nov 04, 2016 2:45 pm

Dr. Jack Cush reviews highlights and reports from this week on, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.

  1. Drug induced cutaneous lupus 88 pts reviewed: most common PPIs, thiazide, antifungals, chemoRx, statins, epileptics
  2. 9 of 10 US physicians surveyed said they'd consider switching a patient from an originator biologic to a biosimilar
  3. Pyoderma gangrenosum (PG) part of other pustular autoinflammatory diseases; PAPA, SAPHO, PASH (PG, acne, hydradenitis)
  4. Juvenile vs adult SLE compared: JSLE is worse w/ more renal, alopecia, oral ulcers, heme, CNS, autoAbs, mortality
  5. Rare reports of tocilizumab related pancreatitis, etiology unclear. Most begin as acute pancreatitis.
  6. Review of pregnancy & lactation says there is insufficient data on RTX, ABA, Kineret, TCZ, Tofa, Stelara, and Benlysta to be used in Pregnancy.
  7. SEL-12 entering Ph 2 trials in gout; a nonimmunogenic pegsiticase (pegylated uricase) combined with SVP-Rapamycin.
  8. Interesting 2 cases of lupus nephritis (Bx Class III & V) onset AFTER 2-3 mos belimumab Rx -wrong drug or too late?
  9. Prevalence of Inflammatory Bowel Disease Increased from 1.8 (1999) to 3.1 million (2015) 
  10. WSJ article on When Cheap Generics Morph into Expensive Prescriptions. Combo drugs like Duexis and Vimovo cost nearly $2000
  11. IgA ACPA and Plasmablasts Point to Microbiome in Pre-Clinical Rheumatoid
  12. Decreased CD4 T Cells with Rituximab Infusions
  13. ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists

The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.